Clinical trials: Large B Cell Diffuse Lymphoma
Lymphoma
Flavopiridol to Treat Relapsed Mantle Cell Lymphoma or Diffuse Large B-Cell Lymphoma
Background: Mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL) are aggressive subtypes of non-Hodgkin lymphoma.
- Trial name
- NCT00445341
- Testing
- Flavopiridol
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
The purpose of this study is to evaluate the efficacy, safety and tolerability of the combination treatment of ibrutinib and MEDI4736 in subjects with relapsed or refractory lymphomas.
- Trial name
- NCT02401048
- Testing
- Ibrutinib, MEDI4736
- Where
- 11 sites in United States
- Volunteers
- 61 people
- Sponsor
- Pharmacyclics LLC.
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib
The goal of this clinical trial was to evaluate whether zanubrutinib can effectively treat adults with CD79B-mutant relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
- Trial name
- NCT05068440
- Testing
- Zanubrutinib
- Where
- 25 sites in China
- Volunteers
- 65 people
- Sponsor
- BeiGene
Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma
Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas
Background: Studies conducted at the National Cancer Institute suggest that certain chemotherapy drugs may be more effective if given by continuous infusion into the vein rather than by the standard method of rapid intravenous…
- Trial name
- NCT01030900
- Testing
- Campath, Rituximab, EPOCH
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
This randomized phase II trial is studying how well giving combination chemotherapy together with rituximab works in treating patients with HIV-associated stage I, stage II, stage III, or stage IV non-Hodgkin's lymphoma.
- Conditions
- AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Immunoblastic Large Cell Lymphoma, AIDS-related Peripheral/Systemic Lymphoma, AIDS-related Small Noncleaved Cell Lymphoma
- Trial name
- NCT00049036
- Testing
- rituximab, etoposide, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 106 people
- Sponsor
- National Cancer Institute (NCI)
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with relapsed lymphoma. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT01258998
- Testing
- Akt inhibitor MK2206, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Large B-cell Lymphoma(DLBCL), Mantle Cell Lymphoma (MCL)
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
Evaluate the safety and tolerability of AMG 562 in adult subjects with DLBCL, MCL, or FL. Estimate the maximum tolerated dose (MTD) and/or a biologically active dose (e.g., recommended phase 2 dose [RP2D])
- Conditions
- Diffuse Large B-cell Lymphoma(DLBCL), Mantle Cell Lymphoma (MCL), Follicular Lymphoma (FL)
- Trial name
- NCT03571828
- Testing
- AMG 562
- Where
- 12 sites in United States, Belgium and 2 more
- Volunteers
- 10 people
- Sponsor
- Amgen
Diffuse Large B Cell Lymphoma
Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL
The standard of care therapy for DLBCL in the relapsed setting is RICE with the plan for the patient to proceed to transplant. This protocol will add Revlimid to the first 7 days of the RICE therapy and again after transplant as…
- Trial name
- RICER (NCT01241734)
- Testing
- Revlimid
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Hackensack Meridian Health
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome
Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
This randomized phase II trial studies how well giving tacrolimus and mycophenolate mofetil (MMF) with or without sirolimus works in preventing acute graft-versus-host disease (GVHD) in patients undergoing donor stem cell…
- Conditions
- Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndrome, Refractory Chronic Lymphocytic Leukemia, Refractory Plasma Cell Myeloma
- Trial name
- NCT00105001
- Testing
- Fludarabine Phosphate, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 210 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors
This study is a dose escalation, and cohort expansion study in subjects with advanced cancer for which no standard therapy exists. Subjects must have received prior treatment for cancer that has not worked, or has stopped working.
- Conditions
- Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Cancer
- Trial name
- NCT02440685
- Testing
- ASN002 Dose Escalation, ASN002 RD
- Where
- 14 sites in United States, Argentina
- Volunteers
- 51 people
- Sponsor
- Asana BioSciences
Lymphoma
Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some find cancer cells and kill them or carry cancer-killing substances to them.
- Trial name
- NCT00278408
- Testing
- filgrastim, rituximab, cyclophosphamide
- Where
- 152 sites in Denmark, Germany and 2 more
- Volunteers
- 700 people
- Sponsor
- German High-Grade Non-Hodgkin's Lymphoma Study Group
Lymphoma, B-cell, Lymphoma, Large B-Cell, Diffuse
Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
The purpose of this randomized, open-label study is to evaluate the safety and efficacy of denintuzumab mafodotin plus RICE (rituximab, ifosfamide, carboplatin, and etoposide) when compared to RICE alone in the treatment of…
- Conditions
- Lymphoma, B-cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Grade 3b, Follicular Lymphoma, Grade 3b
- Trial name
- NCT02592876
- Testing
- denintuzumab mafodotin, rituximab, ifosfamide
- Where
- 29 sites in United States
- Volunteers
- 81 people
- Sponsor
- Seagen Inc.
Lymphoma, Large B-Cell, Diffuse
18F-FDG PET Radiomics of Diffuse Large B-cell Lymphoma
This study aims to investigate the prognostic value of 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) radiomics in diffuse large B-cell lymphoma (DLBCL) and its additional value to the International…
- Trial name
- NCT04317313
- Testing
- FDG PET radiomic feature evaluation
- Where
- China
- Volunteers
- 152 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Diffuse Large B-Cell Lymphoma
Bendamustine, Obinutuzumab, and Dexamethasone in Older Patients With Diffuse Large B-cell Lymphoma
This phase II trial studies how well bendamustine hydrochloride, obinutuzumab, and dexamethasone work in treating older patients with diffuse large B-cell lymphoma.
- Trial name
- NCT02420210
- Testing
- Bendamustine Hydrochloride, Obinutuzumab, Dexamethasone
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Chicago
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma
The goal of this clinical study is to assess whether axicabtagene ciloleucel therapy improves the clinical outcome compared with standard of care second-line therapy in participants with relapsed/refractory diffuse large B-cell…
- Trial name
- ZUMA-7 (NCT03391466)
- Testing
- Axicabtagene Ciloleucel, Platinum-containing Salvage Chemotherapy, Cyclophosphamide
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 359 people
- Sponsor
- Kite, A Gilead Company
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
This phase II trial studies how well rituximab and pembrolizumab with or without lenalidomide works in treating patients with follicular lymphoma and diffuse large B-cell lymphoma that has returned after a period of improvement.
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma
- Trial name
- NCT02446457
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Pembrolizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
TGR-1202 and Ibrutinib in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
This phase IIa trial studies the side effects and how well TGR-1202 and ibrutinib work in treating patients with diffuse large B-cell lymphoma that has returned after a period of improvement or does not respond to treatment.
- Trial name
- NCT02874404
- Testing
- Ibrutinib, Laboratory Biomarker Analysis, PI3K-delta Inhibitor TGR-1202
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Nebraska
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
The purpose of this research study is to evaluate a new investigational drug, TAK-659, given in combination with standard chemotherapy, for the treatment of Diffuse Large B-cell Lymphoma (DLBCL).
- Conditions
- Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT03742258
- Testing
- Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL
This randomized phase III trial studies 90-yttrium ibritumomab tiuxetan and combination chemotherapy compared with combination chemotherapy alone before stem cell transplant in treating patients with diffuse large b-cell…
- Trial name
- SPINOZA (NCT02366663)
- Testing
- 90-Yttrium Ibritumomab tiuxetan, Carmustine, Etoposide
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Chronic Myeloproliferative Disorders, Graft Versus Host Disease
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
This Phase II clinical trial was designed for patients with hematologic malignancies in need of donor peripheral blood stem cell transplant, and have no HLA matched donor.
- Conditions
- Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma
- Trial name
- NCT01116232
- Testing
- anti-thymocyte globulin, rituximab, sirolimus
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute